olmesartan medoxomil has been researched along with Vascular Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XD; Li, JW; Li, Z; Lin, MS; Ni, SK | 1 |
| Mizuno, M; Sada, T | 1 |
2 other study(ies) available for olmesartan medoxomil and Vascular Diseases
| Article | Year |
|---|---|
Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Division; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Monocytes; Muscle, Smooth, Vascular; Neovascularization, Physiologic; Olmesartan Medoxomil; Probability; Sensitivity and Specificity; Tetrazoles; Tumor Necrosis Factor-alpha; Tunica Intima; Vascular Diseases | 2004 |
[Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Heart Diseases; Humans; Hypertension; Imidazoles; Kidney Diseases; Olmesartan Medoxomil; Prodrugs; Tetrazoles; Vascular Diseases | 2004 |